RET and medullary thyroid gland carcinoma: Early data from LIBRETTO-001, the phase I/II study of selpercatinib, showed 56% of patients with RET-mutant MTC previously treated with vandetanib and/or cabozantinib achieved objective responses with mostly grade 1 or 2 adverse events, prompting early approval by the FDA (113).